{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:57:16Z","timestamp":1793422636700,"version":"4.5.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":793,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1093\/annonc\/mdx286","type":"journal-article","created":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T03:10:01Z","timestamp":1496286601000},"page":"2377-2385","source":"Crossref","is-referenced-by-count":863,"title":["Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review"],"prefix":"10.1016","volume":"28","author":[{"given":"L.","family":"Khoja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Wei-Wu Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.L.","family":"Siu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.R.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdx286_bb0010","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1093\/annonc\/mdx286_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"10.1093\/annonc\/mdx286_bb0020","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx286_bb0025","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdx286_bb0030","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1093\/annonc\/mdx286_bb0035","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx286_bb0040","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx286_bb0045","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx286_bb0050","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx286_bb0055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/nrclinonc.2013.245","article-title":"Mitigating the toxic effects of anticancer immunotherapy","volume":"11","author":"Gangadhar","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1093\/annonc\/mdx286_bb0060","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabro","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx286_bb0065","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S2213-2600(15)00092-2","article-title":"Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study","volume":"3","author":"Calabro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"10.1093\/annonc\/mdx286_bb0070","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2008.19.2435","article-title":"Phase I\/II trial of tremelimumab in patients with metastatic melanoma","volume":"27","author":"Camacho","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx286_bb0075","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1200\/JCO.2010.28.3994","article-title":"Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer","volume":"28","author":"Chung","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx286_bb0080","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10637-009-9376-8","article-title":"A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanoma","volume":"29","author":"Hersh","year":"2011","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mdx286_bb0085","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1073\/pnas.0830997100","article-title":"Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients","volume":"100","author":"Hodi","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdx286_bb0090","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/CMR.0000000000000175","article-title":"A phase 2 study of tremelimumab in patients with advanced uveal melanoma","volume":"25","author":"Joshua","year":"2015","journal-title":"Melanoma Res"},{"key":"10.1093\/annonc\/mdx286_bb0095","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1158\/1078-0432.CCR-09-2033","article-title":"Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma","volume":"16","author":"Kirkwood","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx286_bb0100","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/01.cji.0000208259.73167.58","article-title":"Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma","volume":"29","author":"Maker","year":"2006","journal-title":"J Immunother"},{"key":"10.1093\/annonc\/mdx286_bb0105","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx286_bb0110","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","article-title":"Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study","volume":"21","author":"O'Day","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx286_bb0115","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1158\/1078-0432.CCR-09-2870","article-title":"Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma","volume":"16","author":"Ralph","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx286_bb0120","doi-asserted-by":"crossref","first-page":"8968","DOI":"10.1200\/JCO.2005.01.109","article-title":"Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206","volume":"23","author":"Ribas","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx286_bb0125","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/1479-5876-10-236","article-title":"Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion","volume":"10","author":"Ribas","year":"2012","journal-title":"J Transl Med"},{"key":"10.1093\/annonc\/mdx286_bb0130","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1200\/JCO.2012.44.6112","article-title":"Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma","volume":"31","author":"Ribas","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx286_bb0135","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J Immunother"},{"key":"10.1093\/annonc\/mdx286_bb0140","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jhep.2013.02.022","article-title":"A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C","volume":"59","author":"Sangro","year":"2013","journal-title":"J Hepatol"},{"key":"10.1093\/annonc\/mdx286_bb0145","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/annonc\/mdt107","article-title":"Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I\/II study","volume":"24","author":"Slovin","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx286_bb0150","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1158\/1078-0432.CCR-06-2318","article-title":"A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer","volume":"13","author":"Small","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx286_bb0155","first-page":"7","article-title":"Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma","volume":"13","author":"Weber","year":"2013","journal-title":"Cancer Immun"},{"key":"10.1093\/annonc\/mdx286_bb0160","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1200\/JCO.2008.16.1927","article-title":"Phase I\/II study of ipilimumab for patients with metastatic melanoma","volume":"26","author":"Weber","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx286_bb0165","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx286_bb0170","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s00280-015-2873-x","article-title":"Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma","volume":"76","author":"Yamazaki","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdx286_bb0175","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","article-title":"Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis","volume":"30","author":"Yang","year":"2007","journal-title":"J Immunother"},{"key":"10.1093\/annonc\/mdx286_bb0180","doi-asserted-by":"crossref","first-page":"e0118564","DOI":"10.1371\/journal.pone.0118564","article-title":"Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma","volume":"10","author":"Zimmer","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1093\/annonc\/mdx286_bb0185","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx286_bb0190","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx286_bb0195","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx286_bb0200","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of Anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx286_bb0205","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx286_bb0210","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx286_bb0215","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2014.59.0703","article-title":"Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial","volume":"33","author":"Motzer","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx286_bb0220","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/1078-0432.CCR-14-2607","article-title":"Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in patients with advanced solid tumors","volume":"21","author":"Patnaik","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx286_bb0225","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx286_bb0230","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdx286_bb0235","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx286_bb0240","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2013.51.4802","article-title":"Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma","volume":"31","author":"Weber","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx286_bb0245","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx286_bb0250","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdx286_bb0255","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1093\/annonc\/mdx286_bb0260","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx286_bb0265","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1093\/annonc\/mdx286_bb0270","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdx286_bb0275","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1158\/1538-7445.AM2015-2857","article-title":"Abstract 2857: metastatic site and response to pembrolizumab (anti-PD1 antibody) in melanoma","volume":"75","author":"Tumeh","year":"2015","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdx286_bb0280","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/bjc.2016.308","article-title":"Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients","volume":"115","author":"Khoja","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdx286_bb0285","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdx286_bb0290","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"10.1093\/annonc\/mdx286_bb0295","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nm.4321","article-title":"Is autoimmunity the Achilles' heel of cancer immunotherapy?","volume":"23","author":"June","year":"2017","journal-title":"Nat Med"},{"key":"10.1093\/annonc\/mdx286_bb0300","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/art.20280","article-title":"Association of the PD-1.3A allele of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitope","volume":"50","author":"Prokunina","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1093\/annonc\/mdx286_bb0305","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/art.20966","article-title":"A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese","volume":"52","author":"Kong","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1093\/annonc\/mdx286_bb0310","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/annonc\/mdw379.01","article-title":"Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3\u2009mg\/kg vs 10\u2009mg\/kg in patients with metastatic melanoma (MEL)","volume":"27","author":"Ascierto","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx286_bb0315","first-page":"857519","article-title":"Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management","volume":"2013","author":"Tarhini","year":"2013","journal-title":"Scientifica (Cairo)"},{"key":"10.1093\/annonc\/mdx286_bb0320","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdx286_bb0325","doi-asserted-by":"crossref","first-page":"230ra245","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1093\/annonc\/mdx286_bb0330","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1158\/0008-5472.CAN-12-2731","article-title":"Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses","volume":"73","author":"Mitchem","year":"2013","journal-title":"Cancer Res"},{"key":"10.1093\/annonc\/mdx286_bb0335","doi-asserted-by":"crossref","first-page":"687","DOI":"10.2217\/imt-2015-0025","article-title":"Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab","volume":"8","author":"Aya","year":"2016","journal-title":"Immunotherapy"},{"key":"10.1093\/annonc\/mdx286_bb0340","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx286_bb0345","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdx286_bb0350","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdx286_bb0355","doi-asserted-by":"crossref","first-page":"44173","DOI":"10.1038\/srep44173","article-title":"PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis","volume":"7","author":"Wu","year":"2017","journal-title":"Sci Rep."},{"key":"10.1093\/annonc\/mdx286_bb0360","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1093\/annonc\/mdx286_bb0365","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1093\/annonc\/mdv182","article-title":"A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors","volume":"26","author":"Chen","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx286_bb0370","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1093\/annonc\/mdt397","article-title":"Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials","volume":"24","author":"Templeton","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdx286_bb0375","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli","year":"2017","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419349269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419349269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/28\/10\/2377\/20232511\/mdx286.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T22:12:39Z","timestamp":1750284759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419349269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":74,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0923753419349269"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdx286","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]}}}